...
首页> 外文期刊>Journal of nephrology. >Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
【24h】

Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.

机译:在定期用纤维素膜和足够的铁进行透析治疗的患者中,当Kt / N> 1.33时,依泊汀的需要量不取决于透析剂量。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: An inverse correlation between Kt/V and epoetin requirement has recently been demonstrated in stable hemodialysis (HD) patients with adequate iron stores, dialyzed with cellulosic membranes. However, there is no evidence as to whether or not this effect continues for Kt/V even in the adequate or higher range. METHODS: We investigated the relationship between Kt/V and the weekly epoetin dose in 85 stable HD patients (age 63 +/- 16 years) treated with bicarbonate HD and unsubstituted cellulose membranes for 6-338 months (median: 70 months). Inclusion criteria: HD for at least 6 months, subcutaneous rHuEPO for at least 4 months, transferrin saturation (TSAT) > or = 20%, serum ferritin > or = 100 ng/mL, hemoglobin (Hb) level targeted to approximately equal to 12 g/dL for at least 3 months. Exclusion criteria: HBsAg and HIV positivity; need for blood transfusions or evidence of blood loss in the 3 months before the study, acute and chronic infections. To evaluate the effect of dialysis adequacy on the epoetin requirement, we also performed the same analysis after dividing of the patients according to Kt/V. Hematocrit (Hct) and Hb levels were evaluated weekly for 3 weeks; TSAT, serum ferritin, Kt/V, PCRn, serum albumin (sAlb), and weekly epoetin dose were evaluated at the end of observation. No change in dialysis or therapy prescription was made during the study. RESULTS: The results for all the patients were: Hct 36 +/- 2 %, Hb 12 +/- 0.7 g/dL, TSAT 28 +/- 7%, serum ferritin 234 +/- 171 ng/mL, sAlb 4.2 +/- 0.4 g/dL, Kt/V 1.33 +/- 0.17, PCRn 1.15 +/- 0.28 g/Kg/day, weekly epoetin dose 117 +/- 74 U/Kg. There was no correlation between Hb and Kt/V, whereas there was an inverse correlation between the reciprocal of the weekly epoetin dose and Kt/V (r = -0.448, p = 0.0001). Further regression line analysis showed a break-point for Kt/V at the level of 1.33. In the 52 patients with Kt/V < 1.33, the correlation was confirmed between epoetin and Kt/V (r = - 0.563, p = 0.0001), while in the 33 patients with Kt/V > or = 1.33, there was no correlation between epoetin dose and Kt/V (r = 0.021, p = NS). In these patients, multiple regression analysis, with the weekly epoetin dose as a dependent variable, confirmed Kt/V as a non-significant factor. CONCLUSIONS: In iron-replete HD patients on cellulosic membranes and stabilized epoetin therapy, inadequate dialysis was associated with higher epoetin requirement, but for Kt/V values > or = 1.33, there was no further effect on epoetin responsiveness.
机译:背景:最近在稳定的血液透析(HD)患者中,Kt / V与Epoetin需求呈负相关,该患者具有足够的铁储备,并用纤维素膜透析。但是,没有证据表明,即使在适当或更高的范围内,这种影响是否持续Kt / V。方法:我们调查了碳酸氢盐HD和未取代的纤维素膜治疗6-338个月(中位数:70个月)的85名稳定的HD患者(63 +/- 16岁)的Kt / V与每周依泊汀剂量之间的关系。纳入标准:HD至少6个月,皮下rHuEPO至少4个月,转铁蛋白饱和度(TSAT)>或= 20%,血清铁蛋白>或= 100 ng / mL,血红蛋白(Hb)水平的目标值大约等于12 g / dL至少3个月。排除标准:HBsAg和HIV阳性;在研究前3个月内需要输血或失血的证据,包括急慢性感染。为了评估透析充分性对依泊汀需求的影响,我们还在根据Kt / V划分患者后进行了同样的分析。每周评估3周的血细胞比容(Hct)和Hb水平;在观察结束时评估TSAT,血清铁蛋白,Kt / V,PCRn,血清白蛋白(sAlb)和每周的Epoetin剂量。在研究期间没有改变透析或治疗处方。结果:所有患者的结果为:Hct 36 +/- 2%,Hb 12 +/- 0.7 g / dL,TSAT 28 +/- 7%,血清铁蛋白234 +/- 171 ng / mL,sAlb 4.2 + /-0.4 g / dL,Kt / V 1.33 +/- 0.17,PCRn 1.15 +/- 0.28 g / Kg /天,每周的依泊汀剂量117 +/- 74 U / Kg。 Hb和Kt / V之间没有相关性,而每周Epoetin剂量的倒数与Kt / V之间存在反相关性(r = -0.448,p = 0.0001)。进一步的回归线分析显示Kt / V的断裂点位于1.33的水平。在52名Kt / V <1.33的患者中,依泊汀和Kt / V之间存在相关性(r =-0.563,p = 0.0001),而在33名Kt / V>或= 1.33的患者中没有相关性在Epoetin剂量和Kt / V之间(r = 0.021,p = NS)。在这些患者中,以每周的依泊汀剂量作为因变量的多元回归分析证实,Kt / V是不重要的因素。结论:在纤维素膜和稳定的依泊汀治疗的铁补充HD患者中,透析不足与依泊汀需求较高有关,但对于Kt / V值≥1.33,对依泊汀响应性没有进一步影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号